Dr. Ruben Kuruvilla is now offering the first and only cross-linking treatment approved by the U.S. Food and Drug Administration (FDA) for progressive keratoconus and corneal ectasia following refractive surgery, two progressive and sight-threatening eye conditions that affect more than 160,000 Americans. Corneal cross-linking—using Avedro’s Photrexa products and KXL System—is used to stiffen corneas that have been weakened by disease or refractive surgery. Without treatment, patients may go on to require corneal transplants. For more information about this procedure, cross-linking.